(Q40820304)

English

Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study

scientific article published on 4 April 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

maternal health

0 references

1 reference

based on heuristic

inferred from title

Langerhans cell histiocytosis specific to childhood

1 reference

based on heuristic

inferred from title

author name string

Akira Morimoto

1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Yoko Shioda

2

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Toshihiko Imamura

3

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Kazuko Kudo

4

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Hiroshi Kawaguchi

5

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Kazuo Sakashita

6

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Masahiro Yasui

7

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Yuhki Koga

8

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Ryoji Kobayashi

9

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Eiichi Ishii

10

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Junichiro Fujimoto

11

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Keizo Horibe

12

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Fumio Bessho

13

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Yukiko Tsunematsu

14

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Shinsaku Imashuku

15

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

publication date

4 April 2016

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

104

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

99-109

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Nationwide survey of single-system single site Langerhans cell histiocytosis in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

A randomized trial of treatment for multisystem Langerhans' cell histiocytosis

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Pulmonary involvement in pediatric-onset multisystem Langerhans cell histiocytosis: effect on course and outcome

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Cyclosporine A therapy for multisystem langerhans cell histiocytosis.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Recurrent BRAF mutations in Langerhans cell histiocytosis

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-016-1993-3

21 January 2018

Recent advances in Langerhans cell histiocytosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27040279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/27040279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of reactivation on the sequelae of multi-system Langerhans cell histiocytosis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27040279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study

1 reference

https://pubmed.ncbi.nlm.nih.gov/27040279

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-016-1993-3

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40820304&oldid=2204012051"